Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Surgery, Capio St. Göran's Hospital, Stockholm, Sweden.
PLoS One. 2022 Oct 13;17(10):e0274804. doi: 10.1371/journal.pone.0274804. eCollection 2022.
In early breast cancer, neoadjuvant chemotherapy (NACT) is increasingly used. The proof of efficacy is pathologically complete response (pCR), i.e. the absence of invasive tumour in breast and lymph nodes at surgery. Today, pCR is a common endpoint in pharmaceutical trials since it is significantly associated with survival especially in triple-negative and HER2-positive subtypes. Apart from the mitigation of treatment-related toxicity and symptoms, physical exercise mediates anti-tumoral systemic effects associated with tumour regression in preclinical and clinical models. The aim of Neo-ACT is to test the hypothesis that physical exercise can improve pCR rates in breast cancer patients receiving NACT.
The Neo-ACT trial is a prospective clinical trial, randomising T1-3N0-2 breast cancer patients planned for NACT to either a home-based physical exercise intervention supported by a mobile application or routine care. The primary endpoint is pCR; secondary endpoints are patient-reported quality of life, toxicity-related outcomes, and oncological outcomes such as Residual Cancer Burden, objective radiological tumour response, as well as overall, breast cancer-specific and disease-free survival at 2, 5 and 10 years. The intervention consists of a combination of high-intensity interval and resistance training of progressing intensity, and includes at least 150 min of moderate to vigorous physical activity per week, inclusive of two weekly 60-min exercise sessions. In order to show an improvement in pCR of 10%, a total of 712 participants need to be included in the analysis. The Neo-ACT has been registered at clinicaltrials.gov on January 11, 2022 (NCT05184582).
If Neo-ACT can prove the oncological efficacy of physical exercise, implementation of training programmes into NACT schedules will be pursued. The use of a digitally led exercise intervention aims to test the potential of such a strategy for use in rural areas and areas of limited resources.
在早期乳腺癌中,新辅助化疗(NACT)的应用日益增多。疗效的证明是病理完全缓解(pCR),即手术时乳腺和淋巴结中无浸润性肿瘤。如今,pCR 是药物试验中的常见终点,因为它与生存显著相关,尤其是在三阴性和 HER2 阳性亚型中。除了减轻与治疗相关的毒性和症状外,运动还介导了与临床前和临床模型中肿瘤消退相关的抗肿瘤全身效应。Neo-ACT 的目的是检验假设,即运动可以提高接受 NACT 的乳腺癌患者的 pCR 率。
Neo-ACT 试验是一项前瞻性临床试验,将计划接受 NACT 的 T1-3N0-2 期乳腺癌患者随机分为家庭为基础的运动干预组(通过移动应用程序提供支持)和常规护理组。主要终点是 pCR;次要终点是患者报告的生活质量、毒性相关结局以及肿瘤学结局,如残留肿瘤负荷、客观的肿瘤反应,以及 2、5 和 10 年时的总生存率、乳腺癌特异性生存率和无病生存率。干预措施包括高强度间歇训练和渐进式阻力训练的组合,每周至少进行 150 分钟的中等到剧烈体力活动,包括每周两次 60 分钟的运动课程。为了显示 pCR 提高 10%,需要分析总共 712 名参与者。Neo-ACT 已于 2022 年 1 月 11 日在 clinicaltrials.gov 注册(NCT05184582)。
如果 Neo-ACT 能够证明运动的肿瘤学疗效,将进一步将训练计划纳入 NACT 方案。数字化主导的运动干预的使用旨在检验这种策略在农村地区和资源有限地区的应用潜力。